Scrip Asks…What Does 2023 Hold For Biopharma? Part 5: Technological Advances

The confluence of data science and molecular biology fuels expectations among biopharma industry leaders for another year of breakthrough innovation in human therapeutics. More than 70 executives and experts reveal what they are most excited about on the technology front.

Convergence was a recurring theme in the commentary from the 70 or so biopharma leaders who shared with Scrip their predictions around technology. Asked what technological advance would have the biggest impact on biopharma in 2023, they frequently referred to the way multiple scientific advances – in cell and gene therapy, in RNA technologies, in different -omics and so on – would be amplified by advances in artificial intelligence to bring transformative progress across the therapeutic landscape